Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction

Abstract

Current clinically-tested nicotine vaccines have yet shown enhanced smoking cessation efficacy due to their low immunogenicity. Achieving a sufficiently high immunogenicity is a necessity for establishing a clinically-viable nicotine vaccine. This study aims to facilitate the immunogenicity of a hybrid nanoparticle-based nicotine vaccine by rationally incorporating toll-like receptor (TLR)-based adjuvants, including monophosphoryl lipid A (MPLA), Resiquimod (R848), CpG oligodeoxynucleotide 1826 (CpG ODN 1826), and their combinations. The nanoparticle-delivered model adjuvant was found to be taken up more efficiently by dendritic cells than the free counterpart. Nanovaccine particles were transported to endosomal compartments upon cellular internalization. The incorporation of single or dual TLR adjuvants not only considerably increased total anti-nicotine IgG titers but also significantly affected IgG subtype distribution in mice. Particularly, the nanovaccines carrying MPLA+R848 or MPLA+ODN 1826 generated a much higher anti-nicotine antibody titer than those carrying none or one adjuvant. Meanwhile, the anti-nicotine antibody elicited by the nanovaccine adjuvanted with MPLA+R848 had a significantly higher affinity than that elicited by the nanovaccine carrying MPLA+ODN 1826. Moreover, the incorporation of all the selected TLR adjuvants (except MPLA) reduced the brain nicotine levels in mice after nicotine challenge. Particularly, the nanovaccine with MPLA+R848 exhibited the best ability to reduce the level of nicotine entering the brain. Collectively, rational incorporation of TLR adjuvants could enhance the immunological efficacy of the hybrid nanoparticle-based nicotine vaccine, making it a promising next-generation immunotherapeutic candidate for treating nicotine addiction.

Cellular Uptake and Radio-sensitization Effect of Small Gold Nanoparticles in MCF-7 Breast Cancer Cells

“…Depending on the application that can span from disease diagnosis to targeted drug delivery, nanoparticles are constructed from different materials and in different forms such as polymeric, liposome based, dendrimers metals as well as hybrid. For example, liposome-polymeric hybrid nanoparticles showed promising use as immunotherapeutic agent with a potential application in noncancerous and cancerous diseases [9][10][11][12][13], while metal nanoparticles are more frequently explored as imaging and sensitizing probes enhancing radiation therapy [14]. Cancer research has been particularly interested in application of metal based nanoparticles for imaging, targeted drug delivery and radio sensitization in various cancers [15,16].…”

Smoking Cessation Treatments: Current Psychological and Pharmacological Options

“…Nicotine hapten is such a small molecule that it only elicits an immune response when attached to a carrier, such as a protein or NP. Zhao et al designed a series of nanovaccines, and their studies with mice showed that certain types of NPs exhibited the greatest ability to block nicotine from entering the brain 24 . Unfortunately, the assays conducted to date have revealed drawbacks that prevent these systems from achieving higher cessation rates than a placebo 20 .…”

Local delivery of minocycline-loaded PLGA nanoparticles from gelatin-coated neural implants attenuates acute brain tissue responses in mice

“…To improve the therapeutic efficacy and to obtain highly localized effects with less risk of side effects as compared to systemic administration, locally delivered drug loaded biodegradable nanoparticles is an attractive option [18]. Poly (d,l-lactic-co-glycolic acid) (PLGA) nanoparticles have been widely used for a range of biomedical applications, such as drug delivery [19], vaccination [20] and immunomodulation [21]. There is minimal systemic toxicity associated with using PLGA even in the CNS as the polymer undergoes hydrolysis into lactic acid and glycolic acid, which are eliminated from the body through common metabolic pathways [22].…”